![conference banner](/images/conference-banner.jpeg)
Abstract
The occurrence of a plaque-dependent inflammation in Alzheimers disease has been extensively documented in both human specimens and transgenic models of the disease. Since insoluble plaques are present in AD patients from early preclinical stages of the pathology, the point at which neuroinflammation first occurs in the progression of the AD pathology is still unknown. In this review we discuss the clinical and experimental evidence for the occurrence of inflammation in preclinical, asymptomatic phases of the progression of the AD pathology. In particular, we discuss the evidence from different transgenic models suggesting that a pro-inflammatory process might even be initiated prior to plaque deposition. The factors responsible for the early, pre-plaque inflammation are reviewed, with particular emphasis on the role of soluble Aβ-oligomers. Furthermore, we analyze the consequences of the microglial activation and the deregulation of NGF metabolism, in the context of the earliest amyloid pathology. Finally, we propose MMP-9 as a promising biomarker for signalling early stages of an ongoing CNS inflammation.
Keywords: Preclinical Alzheimer's disease, Aβ oligomers, inflammation, transgenic mice, NGF, MMP-9
Current Alzheimer Research
Title: Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?
Volume: 8 Issue: 2
Author(s): M. T. Ferretti and A. C. Cuello
Affiliation:
Keywords: Preclinical Alzheimer's disease, Aβ oligomers, inflammation, transgenic mice, NGF, MMP-9
Abstract: The occurrence of a plaque-dependent inflammation in Alzheimers disease has been extensively documented in both human specimens and transgenic models of the disease. Since insoluble plaques are present in AD patients from early preclinical stages of the pathology, the point at which neuroinflammation first occurs in the progression of the AD pathology is still unknown. In this review we discuss the clinical and experimental evidence for the occurrence of inflammation in preclinical, asymptomatic phases of the progression of the AD pathology. In particular, we discuss the evidence from different transgenic models suggesting that a pro-inflammatory process might even be initiated prior to plaque deposition. The factors responsible for the early, pre-plaque inflammation are reviewed, with particular emphasis on the role of soluble Aβ-oligomers. Furthermore, we analyze the consequences of the microglial activation and the deregulation of NGF metabolism, in the context of the earliest amyloid pathology. Finally, we propose MMP-9 as a promising biomarker for signalling early stages of an ongoing CNS inflammation.
Export Options
About this article
Cite this article as:
T. Ferretti M. and C. Cuello A., Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?, Current Alzheimer Research 2011; 8 (2) . https://dx.doi.org/10.2174/156720511795255982
DOI https://dx.doi.org/10.2174/156720511795255982 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer’s Disease – Future Therapy Based on Dendrimers
Current Neuropharmacology Hypothyroidism and Endothelial Function: A Marker of Early Atherosclerosis?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Comparison of Machine Learning Techniques Based Brain Source Localization Using EEG Signals
Current Medical Imaging Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Current Pharmaceutical Design Impaired DNA Damage Repair as a Common Feature of Neurodegenerative Diseases and Psychiatric Disorders
Current Molecular Medicine Bioactivity Guided Isolation of Quercetin as Anxiolytic Compound from Elaeocarpus ganitrus Beads
The Natural Products Journal Carotid Arterial Stiffness and Cerebral Blood Flow in Amnestic Mild Cognitive Impairment
Current Alzheimer Research A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Dietary Intake and Physical Activity in a Canadian Population Sample of Male Patients with HIV Infection and Metabolic Abnormalities
Current HIV Research An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes
Current Topics in Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry The Effects of Psychological Stress on Depression
Current Neuropharmacology The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease Pharmacogenetics
Current Alzheimer Research Preface
Current Psychopharmacology Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism